Code | CSB-RA018714A2056phHU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IF | 1:20-1:200 |
CUSABIO cloned PRKDC antibody-coding genes into plasma vectors and then transfected these vector clones into mammalian cells using a lipid-based transfection reagent. Following transient expression, the recombinant antibodies against PRKDC were harvested and characterized. The recombinant PRKDC antibody was purified by affinity-chromatography from the culture medium. It can be used to detect PRKDC protein from Human in the ELISA, IF.
Protein kinase, DNA-activated, catalytic polypeptide (PRKDC) encodes a 465 kDa catalytic subunit of DNA-dependent protein kinase that plays a pivotal role in the maintenance of genomic stability and is a critical component of DNA double-strand break repair and recombination. DNA repair genes may serve as potential biomarkers of malignancies or therapeutic targets. Additional analysis showed that a PRKDC mutation was significantly associated with a high mutation load in cervical cancer, colon adenocarcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, gastric adenocarcinoma and endometrial cancer. Patients with gastric cancer or colon cancer harboring PRKDC mutations were also highly associated with MSI-high status. Loss of PRKDC expression is associated with impaired DNA repair. A loss-of-function PRKDC mutation or DNA-PK inhibitor can enhance the efficacy of immune therapy.
There are currently no reviews for this product.